Plain-English translation of NCT06013020 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a certain type of heart attack (called anterior STEMI), some patients develop dangerous blood clots inside the left chamber of the heart. This trial is testing whether adding rivaroxaban—a blood thinner pill—to the standard medications given after a heart attack can prevent these clots from forming. The study wants to make sure this extra medication is safe and actually reduces clot risk.
Blood clots in the heart after this type of attack are a serious complication that can lead to stroke or death. Doctors currently use standard antiplatelet medications, but some patients still develop clots. This medication offers a different approach that might work better, and researchers want to test whether it's both safe and effective.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to one of two groups: one group will take rivaroxaban along with standard heart medications for the first month, then continue with standard medications alone for 11 more months; the other group will take only the standard medications for the full year. You'll have follow-up visits and heart imaging tests at 1 month and 12 months to check for clot formation and monitor your overall health.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China